Topics

ObsEva SA: ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco

01:05 EST 15 Jan 2020 | FinanzNachrichten

Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3 ...

Original Article: ObsEva SA: ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco

NEXT ARTICLE

More From BioPortfolio on "ObsEva SA: ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco"

Quick Search